產品詳情
簡單介紹：
Anti-KIAA1704抗體產品質量穩定，實驗效果明顯，貨期快，價格優惠，歡迎垂詢訂購！我公司長期供應**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關試劑、熒光標記抗體、單克隆抗體、多克隆抗體、各種標記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-KIAA1704抗體用于**組化實驗,WB實驗,相應的標記抗體有HRP標記抗體,FITC標記,BIO等。
詳情介紹：
Rabbit Anti-KIAA1704
Cat. Number:
Anti-KIAA1704抗體KL-17023R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
KIAA1704 is a 340 amino acid protein that is encoded by a gene which maps to chromosome 13. Comprising nearly 4% of human DNA, chromosome 13 contains around 114 million base pairs and 400 genes. Key tumor Anti-KIAA1704抗體suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections. There are four isoforms of KIAA1704 that are produced as a result of alternative splicing events.
Also known as:
AD029; BA245H20.2; Anti-KIAA1704抗體Hypothetical protein LOC55425; K1704_HUMAN; Kiaa1704; Lipopolysaccharide specific response-7 protein; Lipopolysaccharide-specific response protein 7; LSR7; RP11 245H20.2; Uncharacterized protein KIAA1704.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Horse, .
●
Immunogen: KLH conjugated Anti-KIAA1704抗體synthetic peptide derived from human KIAA1704.
●
Predicted Molecular Weight: 38kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-KIAA1704抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
